Company: Avanir Pharmaceuticals
Drug Type: Small Molecule
Conditions: ALS, pseudobulbar affect
Mechanism Type: Sigma-1 receptor (S1R) and NMDA receptor agonist
Mechanism: Nuedexta is Avanir’s first-in-class dual action drugs, which acts on both sigma-1 receptors and NMDA receptors. The precise mechanism of action is not known. Nuedexta diminishes the unpredictable emotional episodes of pseudobulbar affect (PBA) according to clinical studies (Schoedel et al., 2014).
U.S. Status for ALS: FDA Approved
 Enhanced Bulbar Function in Amyotrophic Lateral Sclerosis: The Nuedexta Treatment Trial. Smith, R. et al. Neurotherapeutics. 2017 Jan 9.
 Evaluating the safety and efficacy of dextromethorphan/quinidine in the treatment of pseudobulbar affect. Schoedel, KA et al. Neuropsychiatr Dis Treat. 2014 Jun 26;10:1161-74.
 Clinical Trial Nuedexta in Subjects With ALS. ClinicalTrials.gov, 18 Feb 2015. Accessed 11 Mar 2016 from https://clinicaltrials.gov/ct2/show/NCT01806857.
Last updated June 21st, 2017